Allergan Inc. (NYSE:AGN.)

The analysis of the annual revenue data reveals several noteworthy trends in the company's financial performance over the five-year period ending December 31, 2014.

Eye Care Pharmaceuticals

The revenue from Eye Care Pharmaceuticals showed a consistent and steady increase each year, rising from $2,262,000 thousand in 2010 to $3,257,900 thousand in 2014. This growth indicates a strong and expanding market presence in this segment.

Botox®/Neuromodulators

This category also displayed continuous growth over the period. Revenues increased from $1,419,400 thousand in 2010 to $2,230,600 thousand in 2014, reflecting a robust and accelerating demand for these products.

Skin Care and Other

Revenue from Skin Care and Other experienced moderate growth with a notable jump in 2013, increasing from $292,000 thousand in 2010 to $523,600 thousand by 2014. The significant rise between 2012 and 2013 suggests either product expansion or successful market penetration during that interval.

Specialty Pharmaceuticals

This segment, likely inclusive of the above categories, consistently grew from $3,973,400 thousand in 2010 to $6,012,100 thousand in 2014. The steady increase highlights the segment's importance to overall company revenue and suggests an effective specialization strategy.

Breast Aesthetics

Revenue increased at a moderate pace from $319,100 thousand in 2010 to $406,700 thousand in 2014. Despite growth, the rate appears slower relative to other segments, possibly reflecting more mature or competitive market dynamics.

Obesity Intervention

Obesity Intervention revenues declined sharply from $243,300 thousand in 2010 to $159,500 thousand in 2012, with no recorded data beyond 2012. This suggests discontinuation or divestment of this business line during or after 2012.

Facial Aesthetics

A clear upward trend is evident in Facial Aesthetics revenues, from $283,800 thousand in 2010 to $661,800 thousand in 2014. This substantial growth indicates increasing market acceptance and possibly successful product innovation.

Core Medical Devices

Revenue showed minor fluctuation with an initial rise from $846,200 thousand in 2010 to $924,200 thousand in 2012, followed by a dip in 2013 to $855,400 thousand, and a substantial rebound in 2014 to $1,068,500 thousand. This volatility may indicate challenges and recovery within this segment during the period.

Other

The category labeled Other recorded negligible revenues until 2013, when a small amount appeared ($3,100 thousand), growing to $45,500 thousand in 2014. Though minor, this indicates emerging or miscellaneous income sources becoming more significant.

Medical Devices

Medical Devices revenues closely parallel those of Core Medical Devices, showing a gradual increase from $846,200 thousand in 2010 to $1,114,000 thousand in 2014, inclusive of the fluctuations noted in the Core Medical Devices data.

Product net sales

Overall product net sales exhibited strong and consistent growth from $4,819,600 thousand in 2010 to $7,126,100 thousand in 2014, underscoring the company's expanding market footprint and revenue base during this period.